Keywords
Last Name

Daniel Fuster, MD, PhD

TitleVisiting Researcher
InstitutionBoston University School of Medicine
DepartmentGeneral Internal Medicine
Address801 Massachusetts Ave Crosstown Center
Boston MA 02118
ORCID ORCID Icon0000-0003-1262-5860
 Awards and Honors

Start-EndDescription
2007Catalonian Royal Academy of Medicine. Barcelona.: PhD Thesis Dissertation Award.
2011Spanish Ministry of Education: Postdoctoral grant.
 Self-Described Keywords
  • Alcoholic liver disease
  • Hepatitis C Virus
  • HIV
  • Medical consequences of substance abuse
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sanvisens A, Zuluaga P, Fuster D, Rivas I, Tor J, Marcos M, Chamorro AJ, Muga R. Long-Term Mortality of Patients with an Alcohol-Related Wernicke-Korsakoff Syndrome. Alcohol Alcohol. 2017 Mar 10; 1-6. PMID: 28340112.
    View in: PubMed
  2. Fuster D, Sanvisens A, Bolao F, Zuluaga P, Rivas I, Farré M, Tor J, Muga R. Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. J Addict Med. 2017 Jan/Feb; 11(1):34-39. PMID: 27753720.
    View in: PubMed
  3. Wnuk M, Anderegg MA, Graber WA, Buergy R, Fuster DG, Djonov V. Neuropilin1 regulates glomerular function and basement membrane composition through pericytes in the mouse kidney. Kidney Int. 2017 Apr; 91(4):868-879. PMID: 27988210.
    View in: PubMed
  4. Albano G, Dolder S, Siegrist M, Mercier-Zuber A, Auberson M, Stoudmann C, Hofstetter W, Bonny O, Fuster DG. Increased bone resorption by osteoclast-specific deletion of the sodium/calcium exchanger isoform 1 (NCX1). Pflugers Arch. 2017 Feb; 469(2):225-233. PMID: 27942992.
    View in: PubMed
  5. Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol. 2016 Nov 08; 8(31):1295-1308. PMID: 27872681.
    View in: PubMed
  6. Zuluaga P, Sanvisens A, Teniente A, Fuster D, Tor J, Martínez-Cáceres E, Muga R. Wide array of T-cell subpopulation alterations in patients with alcohol use disorders. Drug Alcohol Depend. 2016 May 1; 162:124-9. PMID: 27038675.
    View in: PubMed
  7. Fuster D, Cheng DM, Wang N, Bernstein JA, Palfai TP, Alford DP, Samet JH, Saitz R. Brief intervention for daily marijuana users identified by screening in primary care: A subgroup analysis of the ASPIRE randomized clinical trial. Subst Abus. 2016 Apr-Jun; 37(2):336-42. PMID: 26453188.
    View in: PubMed
  8. Muga R, Zuluaga P, Sanvisens A, Rivas I, Fuster D, Bolao F, Tor J. Hepatitis C associated to substance abuse: ever closer to a treatment without Interferon. Adicciones. 2015 Jun 17; 27(2):141-9. PMID: 26132303.
    View in: PubMed
  9. Fuster D, Sanvisens A, Bolao F, Zuluaga P, Rivas I, Tor J, Muga R. Markers of inflammation and mortality in a cohort of patients with alcohol dependence. Medicine (Baltimore). 2015 Mar; 94(10):e607. PMID: 25761182.
    View in: PubMed
  10. Muga R, Rivas I, Faure E, Fuster D, Zuluaga P, Rubio M, Muñoz T, Torrens M, Tor J, Sanvisens A. Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. BMC Infect Dis. 2014; 14:504. PMID: 25231321.
    View in: PubMed
  11. Fuster D, Sanvisens A, Bolao F, Serra I, Rivas I, Tor J, Muga R. Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. J Viral Hepat. 2015 Jan; 22(1):18-24. PMID: 25131721.
    View in: PubMed
  12. Fuster D, Cheng DM, Quinn EK, Armah KA, Saitz R, Freiberg MS, Samet JH, Tsui JI. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS. 2014 Apr 24; 28(7):1059-64. PMID: 24401638.
    View in: PubMed
  13. Fuster D, Samet JH, Saitz R. Marijuana use and health in primary care. J Gen Intern Med. 2014 Feb; 29(2):282. PMID: 24234396.
    View in: PubMed
  14. Sanvisens A, Vallecillo G, Bolao F, Rivas I, Fonseca F, Fuster D, Torrens M, Pérez-Hoyos S, Pujol R, Tor J, Muga R. Temporal trends in the survival of drug and alcohol abusers according to the primary drug of admission to treatment in Spain. Drug Alcohol Depend. 2014 Mar 1; 136:115-20. PMID: 24485061.
    View in: PubMed
  15. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, Tsui JI. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014 Jan; 109(1):62-70. PMID: 24112091.
    View in: PubMed
  16. Fuster D, Cheng DM, Allensworth-Davies D, Palfai TP, Samet JH, Saitz R. No detectable association between frequency of marijuana use and health or healthcare utilization among primary care patients who screen positive for drug use. J Gen Intern Med. 2014 Jan; 29(1):133-9. PMID: 24048656.
    View in: PubMed
  17. Fuster D, Tsui JI, Cheng DM, Quinn EK, Armah KA, Nunes D, Freiberg MS, Samet JH. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses. 2013 Aug; 29(8):1110-6. PMID: 23601055.
    View in: PubMed
  18. Fuster D, Tsui JI, Cheng DM, Quinn EK, Bridden C, Nunes D, Libman H, Saitz R, Samet JH. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res. 2013 Sep; 37(9):1527-35. PMID: 23647488.
    View in: PubMed
  19. Sanvisens A, Rivas I, Faure E, Muñoz T, Rubio M, Fuster D, Tor J, Muga R. [Characteristics of heroin dependent patients admitted to a methadone treatment program]. Med Clin (Barc). 2014 Jan 21; 142(2):53-8. PMID: 23337454.
    View in: PubMed
  20. Rivas I, Sanvisens A, Bolao F, Fuster D, Tor J, Pujol R, Torrens M, Rey-Joly C, Muga R. Impact of medical comorbidity and risk of death in 680 patients with alcohol use disorders. Alcohol Clin Exp Res. 2013 Jan; 37 Suppl 1:E221-7. PMID: 23320801.
    View in: PubMed
  21. Muga R, Sanvisens A, Fuster D, Tor J, Martínez E, Pérez-Hoyos S, Muñoz A. Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One. 2012; 7(10):e46810. PMID: 23056462.
    View in: PubMed
  22. Fuster D, Tor J, Rey-Joly C, Muga R. [Pathogenic interactions between alcohol and hepatitis C]. Med Clin (Barc). 2012 May 19; 138(14):627-32. PMID: 21696783.
    View in: PubMed
  23. Sanvisens A, Fuster D, Serra I, Tor J, Tural C, Rey-Joly C, Muga R. Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users. Curr HIV Res. 2011 Jun; 9(4):256-62. PMID: 21675942.
    View in: PubMed
  24. Rosón B, Monte R, Gamallo R, Puerta R, Zapatero A, Fernández-Solá J, Pastor I, Girón JA, Laso J. Prevalence and routine assessment of unhealthy alcohol use in hospitalized patients. Eur J Intern Med. 2010 Oct; 21(5):458-64. PMID: 20816605.
    View in: PubMed
  25. Rivas I, Martinez E, Sanvisens A, Bolao F, Tor J, Torrens M, Pujol R, Fuster D, Rey-Joly C, Muñoz A, Muga R. Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987-2006. Drug Alcohol Depend. 2010 Aug 1; 110(3):234-9. PMID: 20456873.
    View in: PubMed
  26. Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl. 2009 Sep; 15(9):1133-41. PMID: 19718643.
    View in: PubMed
  27. Fuster D, Sierra A, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Garcia Del Muro X, Maurel J. Correlation between spiral CT and PET in patients with advanced GIST refractory to high-dose imatinib: A GEIS study. J Clin Oncol. 2009 May 20; 27(15_suppl):10553. PMID: 27963949.
    View in: PubMed
  28. Langohr K, Sanvisens A, Fuster D, Tor J, Serra I, Rey-Joly C, Rivas I, Muga R. Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients. Open AIDS J. 2008; 2:82-8. PMID: 19274066.
    View in: PubMed
  29. Miro JM, Aguero F, Laguno M, Tuset M, Cervera C, Moreno A, Garcia-Valdecasas JC, Rimola A. Liver transplantation in HIV/hepatitis co-infection. J HIV Ther. 2007 Mar; 12(1):24-35. PMID: 17589393.
    View in: PubMed
  30. Fumaz CR, Muñoz-Moreno JA, Ballesteros AL, Paredes R, Ferrer MJ, Salas A, Fuster D, Masmitjà E, Pérez-Alvarez N, Gómez G, Tural C, Clotet B. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care. 2007 Jan; 19(1):138-45. PMID: 17129869.
    View in: PubMed
  31. Solà R, Galeras JA, Montoliu S, Tural C, Force L, Torra S, Montull S, Castro ER, Coll S, Fuster D, Barrufet P, Sirera G, Giménez MD, Clotet B, Planas R. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses. 2006 May; 22(5):393-400. PMID: 16706615.
    View in: PubMed
  32. Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaró J, Roget M, García I, Pedrol E, Tor J, Ballesteros AL, Salas A, Sirera G, Videla S, Clotet B, Tural C. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther. 2006; 11(4):473-82. PMID: 16856621.
    View in: PubMed
  33. Fuster D, Clotet B. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother. 2005 Aug; 6(9):1565-72. PMID: 16086644.
    View in: PubMed
  34. Ballesteros AL, Fuster D, Planas R, Clotet B, Tural C. Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother. 2005 Jun; 55(6):824-7. PMID: 15886264.
    View in: PubMed
  35. Fuster D, Huertas JA, Gómez G, Solà R, González García J, Vilaró J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther. 2005; 10(7):841-7. PMID: 16312180.
    View in: PubMed
  36. Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabré E, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Tural C. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses. 2004 Dec; 20(12):1293-7. PMID: 15650421.
    View in: PubMed
  37. Ballesteros AL, Miró O, López S, Fuster D, Videla S, Martínez E, Garrabou G, Salas A, Côté H, Tor J, Rey-Joly C, Planas R, Clotet B, Tural C. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both. Antivir Ther. 2004 Dec; 9(6):969-77. PMID: 15651755.
    View in: PubMed
  38. Carles J, Monzo M, Artells R, Amat M, Foro P, Fuster D, Alameda F, Sanchez JM, Fontane J, Sanchez J. XPC, XPD/ERCC2, UMPS, CYP1b1 and XRCC5, single nucleotide polymorphisms (SNPs) in head and neck cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5588. PMID: 28014072.
    View in: PubMed
  39. Ibeas R, Monzo M, Moreno I, Hernandez R, Campayo M, Pie J, Fuster D, Torres G, Alcaide A, Jove J. Cytidine Deaminase (CD) and Dihydropyrimidine Dehydrogenase (DPD) single nucleotide polymorphisms (SNPs) in capecitabine-treated colorectal cancer (CRC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3662. PMID: 28014652.
    View in: PubMed
  40. Lloveras B, Monzo M, Colomer R, Llombart A, Ramos M, Mayordomo JI, Fuster D, Alba E. Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. J Clin Oncol. 2004 Jul 15; 22(14_suppl):507. PMID: 28016103.
    View in: PubMed
  41. Ballesteros AL, Franco S, Fuster D, Planas R, Martínez MA, Acosta L, Sirera G, Salas A, Tor J, Rey-Joly C, Clotet B, Tural C. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS. 2004 Jan 2; 18(1):59-66. PMID: 15090830.
    View in: PubMed
  42. Fuster D, Clotet B. Chronic HCV infection in HIV-positive patients: a new challenge. J Int Assoc Physicians AIDS Care (Chic). 2003 Apr-Jun; 2(2):56-8. PMID: 12961758.
    View in: PubMed
  43. Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, Lasanta JA, Planas R, Rey-Joly C, Clotet B. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat. 2003 Mar; 10(2):118-25. PMID: 12614468.
    View in: PubMed
Daniel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department